Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Coronavirus Disease 2019 (COVID-19): Current Situation and Therapeutic Options

Author(s): Veer Singh and Vishal Mishra*

Volume 2, Issue 4, 2021

Published on: 05 October, 2020

Page: [481 - 491] Pages: 11

DOI: 10.2174/2666796701999201005211854

Abstract

Coronavirus disease 2019 (COVID-19) is defined as an illness caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). COVID-19 was first reported in the Wuhan, China, in late December, 2019. The World Health Organization (WHO) declared COVID-19 a global emergency on March 11, 2020. COVID-19 was rapidly transmitted and caused infection in 21,294,845 people and 761,779 deaths in more than 213 countries worldwide till August 16, 2020. United States of America (USA), Brazil, India, Russia Federation, Peru, Mexico, Colombia, Spain, France, Italy, Germany, and United Kingdom (UK) stand top COVID-19 affected countries in the world. The high transmission rate of COVID-19 might be due to large viral incubation time (2-14 days) and some modifications in the spike glycoprotein. Currently, effective drugs or vaccines are not developed for the treatment of novel coronavirus. However, few antibiotics like hydroxychloroquine and remdesivir have been currently used for the treatment of COVID-19 infection. Several collaboratives are working together for developing an effective and safe vaccine against COVID-19 and few vaccines are under clinical trial. Scientists are also working on plasma therapy and monoclonal antibodies. Nowadays, plasma therapy is considered the most effective treatment against COVID-19 and some promising results have been achieved. This review focuses on several therapeutic options for COVID-19, such as anti-viral drugs, vaccines, plasma therapy, and monoclonal antibodies. This review also covers the current situations of COVID-19 in the world. This review is about COVID-19, which will be beneficial to researchers for the development of potential treatment against it.

Keywords: SARS-CoV-2, COVID-19, anti-viral drugs, plasma therapy, vaccine, monoclonal antibodies.

Graphical Abstract

[1]
Zumla A, Chan JFW, Azhar EI, Hui DSC, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 2016; 15(5): 327-47.
[http://dx.doi.org/10.1038/nrd.2015.37] [PMID: 26868298]
[2]
World Health Organization (WHO). Coronavirus disease (COVID-19). Situation Report-209. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200816-covid-19-sitrep-209.pdf?sfvrsn=5dde1ca2_2
[3]
Worldometer. Corona Meter. Available from: https://www.worldometers.info/coronavirus/?%20
[4]
Nadeem MS, Zamzami MA, Choudhry H, et al. Origin, potential therapeutic targets and treatment for coronavirus disease (COVID-19). Pathogens 2020; 9(4): 307-19.
[http://dx.doi.org/10.3390/pathogens9040307] [PMID: 32331255]
[5]
Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents 2020; 55(5)105951
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105951] [PMID: 32234466]
[6]
Yi Y, Lagniton PNP, Ye S, Li E, Xu RH. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci 2020; 16(10): 1753-66.
[http://dx.doi.org/10.7150/ijbs.45134] [PMID: 32226295]
[7]
Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. Clin Immunol 2020; 215: 108448-60.
[http://dx.doi.org/10.1016/j.clim.2020.108448] [PMID: 32353634]
[8]
Lu D. Inside Wuhan’s lockdown. New Sci 2020; 245(3268): 7-7.
[http://dx.doi.org/10.1016/S0262-4079(20)30234-7] [PMID: 32287788]
[9]
Lamba I. Why India needs to extend the nationwide lockdown. Am J Emerg Med 2020; 38(7): 1528-9.
[http://dx.doi.org/10.1016/j.ajem.2020.04.026] [PMID: 32307297]
[10]
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8(4): 420-2.
[http://dx.doi.org/10.1016/S2213-2600(20)30076-X] [PMID: 32085846]
[11]
Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019; 17(3): 181-92.
[http://dx.doi.org/10.1038/s41579-018-0118-9] [PMID: 30531947]
[12]
Qian Z, Travanty EA, Oko L, et al. Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome-coronavirus. Am J Respir Cell Mol Biol 2013; 48(6): 742-8.
[http://dx.doi.org/10.1165/rcmb.2012-0339OC] [PMID: 23418343]
[13]
Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495(7440): 251-4.
[http://dx.doi.org/10.1038/nature12005] [PMID: 23486063]
[14]
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270-3.
[http://dx.doi.org/10.1038/s41586-020-2012-7] [PMID: 32015507]
[15]
Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 56(1): 105949-54.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105949] [PMID: 32205204]
[16]
Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid anti-viral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 2020; 50(4): 384-4.
[http://dx.doi.org/10.1016/j.medmal.2020.03.006] [PMID: 32240719]
[17]
Chen J, Ping L, Liu L, et al. A pilot study of hydroxychloroquine sulfate in patients with common 2019 coronavirus disease-19 (COVID-19). J ZheJiang Univ Med Sci 2020; 49: 215-9.
[18]
Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial.medRxiv 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v3
[19]
Venkat Kumar G, Jeyanthi V, Ramakrishnan S. A short review on antibody therapy for COVID-19. New Microbes New Infect 2020; 35: 100682-5.
[http://dx.doi.org/10.1016/j.nmni.2020.100682] [PMID: 32313660]
[20]
de Olano J, Howland MA, Su MK, Hoffman RS, Biary R. Toxicokinetics of hydroxychloroquine following a massive overdose. Am J Emerg Med 2019; 37(12): 2264.e5-8.
[http://dx.doi.org/10.1016/j.ajem.2019.158387] [PMID: 31477360]
[21]
Ali I, Alharbi OML. COVID-19: Disease, management, treatment, and social impact. Sci Total Environ 2020; 728: 138861-6.
[http://dx.doi.org/10.1016/j.scitotenv.2020.138861] [PMID: 32344226]
[22]
Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr 2020; 14(3): 241-6.
[http://dx.doi.org/10.1016/j.dsx.2020.03.011] [PMID: 32247211]
[23]
Baron SA, Devaux C, Colson P, Raoult D, Rolain JM. Teicoplanin: an alternative drug for the treatment of COVID-19? Int J Antimicrob Agents 2020; 55(4): 105944-5.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105944] [PMID: 32179150]
[24]
Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the anti-viral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 2018; 9(2): 221-35.
[http://dx.doi.org/10.1128/mBio.00221-18] [PMID: 29511076]
[25]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[26]
Barragan P, Podzamczer D. Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment. Expert Opin Pharmacother 2008; 9(13): 2363-75.
[http://dx.doi.org/10.1517/14656566.9.13.2363] [PMID: 18710360]
[27]
Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382(19): 1787-99.
[http://dx.doi.org/10.1056/NEJMoa2001282] [PMID: 32187464]
[28]
Furuta Y, Takahashi K, Kuno-Maekawa M, et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005; 49(3): 981-6.
[http://dx.doi.org/10.1128/AAC.49.3.981-986.2005] [PMID: 15728892]
[29]
Express Pharma. Glenmark announces top-line results from Phase 3 clinical trial of favipiravir for COVID-19 treatment Available from: https://www.expresspharma.in/covid19-updates/glenmark-announces-top-line-results-from-phase-3-clinical-trial-of-favipiravir-for-covid-19-treatment/
[30]
U. S. National Library of Medicine. The safety of EIDD-2801 and its effect on viral shedding of SARS-CoV-2 (end COVID). Available from: https://clinicaltrials.gov/ct2/show/NCT04405739
[31]
Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable broad-spectrum anti-viral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med 2020; 12(541)eabb5883
[http://dx.doi.org/10.1126/scitranslmed.abb5883] [PMID: 32253226]
[32]
Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis 2003; 3(11): 722-7.
[http://dx.doi.org/10.1016/S1473-3099(03)00806-5] [PMID: 14592603]
[33]
U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and
[34]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[35]
Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 2003; 9(6): 399-406.
[PMID: 14660806]
[36]
Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. J Med Virol 2020; 92(6): 556-63.
[http://dx.doi.org/10.1002/jmv.25729] [PMID: 32104907]
[37]
Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013; 19(10): 1313-7.
[http://dx.doi.org/10.1038/nm.3362] [PMID: 24013700]
[38]
Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci 2020; 248: 117477-82.
[http://dx.doi.org/10.1016/j.lfs.2020.117477] [PMID: 32119961]
[39]
Mulangu S, Dodd LE, Davey RT Jr, et al. PALM Writing Group. PALM consortium study team. Consortium study team, P.A.L.M. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019; 381(24): 2293-303.
[http://dx.doi.org/10.1056/NEJMoa1910993] [PMID: 31774950]
[40]
Holshue ML, DeBolt C, Lindquist S, et al. Washington State 2019-nCoV Case Investigation Team. Washington State 2019-nCoV case Investigation Team. First case of 2019 novel Coronavirus in the United States. N Engl J Med 2020; 382(10): 929-36.
[http://dx.doi.org/10.1056/NEJMoa2001191] [PMID: 32004427]
[41]
Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother 2020; 64(5): 1-7.
[http://dx.doi.org/10.1128/AAC.00399-20] [PMID: 32152082]
[42]
Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the anti-viral effects of chloroquine. Lancet Infect Dis 2006; 6(2): 67-9.
[http://dx.doi.org/10.1016/S1473-3099(06)70361-9] [PMID: 16439323]
[43]
Yan Y, Zou Z, Sun Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res 2013; 23(2): 300-2.
[http://dx.doi.org/10.1038/cr.2012.165] [PMID: 23208422]
[44]
Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 2007; 30(4): 297-308.
[http://dx.doi.org/10.1016/j.ijantimicag.2007.05.015] [PMID: 17629679]
[45]
Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005; 2: 69-78.
[http://dx.doi.org/10.1186/1743-422X-2-69] [PMID: 16115318]
[46]
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14(1): 72-3.
[http://dx.doi.org/10.5582/bst.2020.01047] [PMID: 32074550]
[47]
Pereira BB. Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review. J Toxicol Environ Health B Crit Rev 2020; 23(4): 177-81.
[http://dx.doi.org/10.1080/10937404.2020.1752340] [PMID: 32281481]
[48]
Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020; 55(4)105932
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105932] [PMID: 32145363]
[49]
Jallouli M, Galicier L, Zahr N, et al. Plaquenil lupus systemic study group. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheumatol 2015; 67(8): 2176-84.
[http://dx.doi.org/10.1002/art.39194] [PMID: 25989906]
[50]
Yao X, Ye F, Zhang M, et al. In vitro anti-viral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; 71(15): 732-9.
[http://dx.doi.org/10.1093/cid/ciaa237] [PMID: 32150618]
[51]
Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020; 16(3): 155-66.
[http://dx.doi.org/10.1038/s41584-020-0372-x ] [PMID: 32034323]
[52]
Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020; 20(4): 398-400.
[http://dx.doi.org/10.1016/S1473-3099(20)30141-9] [PMID: 32113510]
[53]
Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24(1): 44-6.
[http://dx.doi.org/10.1007/s10096-004-1271-9] [PMID: 15616839]
[54]
Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007; 357(14): 1450-1.
[http://dx.doi.org/10.1056/NEJMc070359 ] [PMID: 17914053]
[55]
Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52(4): 447-56.
[http://dx.doi.org/10.1093/cid/ciq106] [PMID: 21248066]
[56]
Ko JH, Seok H, Cho SY, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther (Lond) 2018; 23(7): 617-22.
[http://dx.doi.org/10.3851/IMP3243] [PMID: 29923831]
[57]
Dodd RY. Emerging pathogens and their implications for the blood supply and transfusion transmitted infections. Br J Haematol 2012; 159(2): 135-42.
[http://dx.doi.org/10.1111/bjh.12031] [PMID: 22924410]
[58]
Chen L, Liu HG, Liu W, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43(3): 203-8.
[PMID: 32164089]
[59]
Ankcorn M, Gallacher J, Ijaz S, et al. Convalescent plasma therapy for persistent hepatitis E virus infection. J Hepatol 2019; 71(2): 434-8.
[http://dx.doi.org/10.1016/j.jhep.2019.04.008] [PMID: 31075322]
[60]
Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020; 323(16): 1582-9.
[http://dx.doi.org/10.1001/jama.2020.4783] [PMID: 32219428]
[61]
India today. India's first Covid-19 patient treated with plasma therapy recovers. Available from: https://www.indiatoday.in/india/story/india-s-first-to-be-treated-with-plasma-therapy-covid-19-patient-recovers-1671339-2020-04-26
[62]
Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA 2020; 323(16): 1561-2.
[http://dx.doi.org/10.1001/jama.2020.4940] [PMID: 32219429]
[63]
Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA 2020; 117(17): 9490-6.
[http://dx.doi.org/10.1073/pnas.2004168117] [PMID: 32253318]
[64]
U.S. food and drug administration. Investigational covid-19 convalescent plasma-emergency INDs Available from: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma
[65]
Livemint. First Covid-19 patient to undergo plasma therapy in Maharashtra dies in Mumbai. Available from: https://www.livemint.com/news/india/first-coronavirus-patient-to-undergo-plasma-therapy-in-maharashtra-dies-in-mumbai-11588304953927.html
[66]
Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun 2020; 11(1): 2251-6.
[http://dx.doi.org/10.1038/s41467-020-16256-y] [PMID: 32366817]
[67]
Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol 2020; 38(1): 10-8.
[PMID: 32134278]
[68]
Tomita M, Tsumoto K. Hybridoma technologies for antibody production. Immunotherapy 2011; 3(3): 371-80.
[http://dx.doi.org/10.2217/imt.11.4] [PMID: 21395379]
[69]
Apiratmateekul N, Phunpae P, Kasinrerk W. A modified hybridoma technique for production of monoclonal antibodies having desired isotypes. Cytotechnology 2009; 60(1-3): 45-51.
[http://dx.doi.org/10.1007/s10616-009-9213-0] [PMID: 19639389]
[70]
Lee SH, Han BS, Choe J, Sin JI. Preferential production of IgM-secreting hybridomas by immunization with DNA vaccines coding for Ebola virus glycoprotein: use of protein boosting for IgG-secreting hybridoma production. Clin Exp Vaccine Res 2017; 6(2): 135-45.
[http://dx.doi.org/10.7774/cevr.2017.6.2.135] [PMID: 28775978]
[71]
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020; 181(2): 281-292.e6.
[http://dx.doi.org/10.1016/j.cell.2020.02.058] [PMID: 32155444]
[72]
Tai W, He L, Zhang X, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol 2020; 17(6): 613-20.
[http://dx.doi.org/10.1038/s41423-020-0400-4] [PMID: 32203189]
[73]
Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. J Virol 2020; 94(7): 127-20.
[http://dx.doi.org/10.1128/JVI.00127-20] [PMID: 31996437]
[74]
Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med 2020; 26(4): 450-2.
[http://dx.doi.org/10.1038/s41591-020-0820-9] [PMID: 32284615]
[75]
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE-2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181(2): 271-280.e8.
[http://dx.doi.org/10.1016/j.cell.2020.02.052] [PMID: 32142651]
[76]
Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 2020; 11(1): 1620-31.
[http://dx.doi.org/10.1038/s41467-020-15562-9] [PMID: 32221306]
[77]
Rossi JF, Lu ZY, Jourdan M, Klein B. Interleukin-6 as a therapeutic target. Clin Cancer Res 2015; 21(6): 1248-57.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-2291] [PMID: 25589616]
[78]
National health and family planning commission of China (NHPFC). Chinese clinical guidance for COVID 19 pneumonia diagnosis and treatment. Available from: http://kjfy.meetingchina.org/msite/news/show/cn/3337.html
[79]
Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Devel Ther 2017; 11: 1593-603.
[http://dx.doi.org/10.2147/DDDT.S100302] [PMID: 28579757]
[80]
Zhang J, Xie B, Hashimoto K. Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav Immun 2020; 87: 59-73.
[http://dx.doi.org/10.1016/j.bbi.2020.04.046] [PMID: 32334062]
[81]
Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3(5): 391-400.
[http://dx.doi.org/10.1038/nrd1381] [PMID: 15136787]
[82]
Sui J, Li W, Murakami A, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci USA 2004; 101(8): 2536-41.
[http://dx.doi.org/10.1073/pnas.0307140101] [PMID: 14983044]
[83]
Tian X, Li C, Huang A, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect 2020; 9(1): 382-5.
[http://dx.doi.org/10.1080/22221751.2020.1729069] [PMID: 32065055]
[84]
van den Brink EN, Ter Meulen J, Cox F, et al. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J Virol 2005; 79(3): 1635-44.
[http://dx.doi.org/10.1128/JVI.79.3.1635-1644.2005] [PMID: 15650189]
[85]
Pronker ES, Weenen TC, Commandeur H, Claassen EHJHM, Osterhaus ADME. Risk in vaccine research and development quantified. PLoS One 2013; 8(3)e57755
[http://dx.doi.org/10.1371/journal.pone.0057755] [PMID: 23526951]
[86]
Pang J, Wang MX, Ang IYH, et al. Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review. J Clin Med 2020; 9(3): 623-55.
[http://dx.doi.org/10.3390/jcm9030623] [PMID: 32110875]
[87]
World Health Organization (WHO). DRAFT landscape of COVID-19 candidate vaccines. Available form: https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf
[88]
INOVIO. Powering and medicines Available form: https://www.inovio.com/dna-medicines-pipeline/
[89]
Labiotech.edu. BioNTech and Pfizer’s mRNA vaccine for Covid-19 tested in humans Available form: https://www.labiotech.eu/medical/biontech-coronavirus-vaccine-china-partnership
[90]
Science. COVID-19 vaccine protects monkeys from new coronavirus, Chinese biotech reports. Available form: https://www.sciencemag.org/news/2020/04/covid-19-vaccine-protects-monkeys-new-coronavirus-chinese-biotech-reports
[91]
CurVac. CureVac CEO Daniel Menichella discusses coronavirus vaccine development with US President Donald Trump and members of Coronavirus task force Available form: https://www.curevac.com/news/curevac-ceo-daniel-menichella-ber%C3%A4t-mit-us-pr%C3%A4sident-donald-trump-und-mitgliedern-der-corona-task-force-entwicklungsm%C3%B6glichkeiten-eines-coronavirus-impfstoffes
[92]
GlaxoSmithKline plc (GSK). GSK actions to support the global response to COVID-19 Available form https://www.gsk.com/en-gb/media/resource-centre/our-contribution-to-the-fight-against-2019-ncov
[93]
Dynavax. Valneva and Dynavax announce collaboration to advance vaccine development for COVID-19. Available form: http://investors.dynavax.com/news-releases/news-release-details/valneva-and-dynavax-announce-collaboration-advance-vaccine
[94]
Scientific American. Sanofi announces it will work with HHS to develop coronavirus vaccine. Available form: https://www.scientificamerican.com/article/sanofi-announces-it-will-work-with-hhs-to-develop-coronavirus-vaccine
[95]
Sision PR. Codagenix and serum institute of India initiate codevelopment of a scalable, live-Attenuated vaccine against the 2019 novel coronavirus, COVID-19. Available form: https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html?tc=eml_cleartime
[96]
Wisconsin Alumni Research Foundation. UW–Madison, FluGen, Bharat biotech to develop CoroFlu, a coronavirus vaccine. Available form: https://www.warf.org/news-media/news/releases-and-announcements/uw-madison-flugen-bharat-biotech-to-develop-coroflu-a-coronavirus-vaccine.cmsx
[97]
Scrip informa pharma intelligence. Moderna stands alone with single-antigen approach to COVID-19 vaccine. Available form: https://scrip.pharmaintelligence.informa.com/SC142010/Moderna-Stands-Alone-With-SingleAntigen-Approach-To-COVID19-Vaccine
[98]
The pharma letters. J & J working on coronavirus vaccine. Available form: https://www.thepharmaletter.com/article/j-j-working-on-coronavirus-vaccine
[99]
Cheung E. China coronavirus: Hong Kong researchers have already developed vaccine but need time to test it, expert reveals. South China morning post. Available form: https://www.scmp.com/news/hong-kong/health-environment/article/3047956/china-coronavirus-hong-kong-researchers-have
[100]
Jiang S, Bottazzi ME, Du L, et al. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines 2012; 11(12): 1405-13.
[http://dx.doi.org/10.1586/erv.12.126] [PMID: 23252385]
[101]
Coleman CM, Liu YV, Mu H, et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 2014; 32(26): 3169-74.
[http://dx.doi.org/10.1016/j.vaccine.2014.04.016] [PMID: 24736006]
[102]
Chen WH, Chag SM, Poongavanam MV, et al. Optimization of the production process and characterization of the yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1), a SARS vaccine candidate J Pharm Sci 2017; 106(8): 1961-70.
[http://dx.doi.org/10.1016/j.xphs.2017.04.037] [PMID: 28456726]

Rights & Permissions Print Cite
Article Metrics
18
1
© 2024 Bentham Science Publishers | Privacy Policy